Welcome to LookChem.com Sign In|Join Free

CAS

  • or
1H-Pyrrolo[2,3-b]pyridin-5-ol, 1-[tris(1-methylethyl)silyl]is a complex and unique chemical compound belonging to the class of pyrrolopyridines, which are heterocyclic aromatic organic compounds. Characterized by the presence of a tris(1-methylethyl)silyl group, this compound is primarily of interest in advanced chemical research and experimentation due to its potential biological activities. However, detailed information about its specific properties, uses, and safety measures is not widely available.

685514-01-6 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 685514-01-6 Structure
  • Basic information

    1. Product Name: 1H-Pyrrolo[2,3-b]pyridin-5-ol, 1-[tris(1-methylethyl)silyl]-
    2. Synonyms: 1H-Pyrrolo[2,3-b]pyridin-5-ol, 1-[tris(1-methylethyl)silyl]-;1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridin-5-ol;1-[Tris(1-methylethyl)silyl]-1H-pyrrolo[2,3-b]pyridin-5-ol;1-triisopropylsilylpyrrolo[2,3-b]pyridin-5-ol;1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-sulfonic acid
    3. CAS NO:685514-01-6
    4. Molecular Formula: C16H26N2OSi
    5. Molecular Weight: 290.48
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 685514-01-6.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 341.6°C at 760 mmHg
    3. Flash Point: 160.4°C
    4. Appearance: /
    5. Density: 1.03g/cm3
    6. Vapor Pressure: 4.03E-05mmHg at 25°C
    7. Refractive Index: 1.534
    8. Storage Temp.: N/A
    9. Solubility: N/A
    10. PKA: 8.50±0.40(Predicted)
    11. CAS DataBase Reference: 1H-Pyrrolo[2,3-b]pyridin-5-ol, 1-[tris(1-methylethyl)silyl]-(CAS DataBase Reference)
    12. NIST Chemistry Reference: 1H-Pyrrolo[2,3-b]pyridin-5-ol, 1-[tris(1-methylethyl)silyl]-(685514-01-6)
    13. EPA Substance Registry System: 1H-Pyrrolo[2,3-b]pyridin-5-ol, 1-[tris(1-methylethyl)silyl]-(685514-01-6)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 685514-01-6(Hazardous Substances Data)

685514-01-6 Usage

Uses

Used in Pharmaceutical and Medicinal Chemistry:
1H-Pyrrolo[2,3-b]pyridin-5-ol, 1-[tris(1-methylethyl)silyl]is used as a compound of interest for its potential biological activities, particularly in the development of new pharmaceuticals and medicinal agents. Its unique structure and properties make it a promising candidate for further research and development in this field.
Used in Advanced Chemical Research and Experimentation:
1H-Pyrrolo[2,3-b]pyridin-5-ol, 1-[tris(1-methylethyl)silyl]is used as a subject of study in advanced chemical research and experimentation. Its complex structure and potential applications in various fields make it a valuable compound for scientists and researchers to explore and understand its properties and possible uses.

Check Digit Verification of cas no

The CAS Registry Mumber 685514-01-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,8,5,5,1 and 4 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 685514-01:
(8*6)+(7*8)+(6*5)+(5*5)+(4*1)+(3*4)+(2*0)+(1*1)=176
176 % 10 = 6
So 685514-01-6 is a valid CAS Registry Number.
InChI:InChI=1/C16H26N2OSi/c1-11(2)20(12(3)4,13(5)6)18-8-7-14-9-15(19)10-17-16(14)18/h7-13,19H,1-6H3

685514-01-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-sulfonic acid

1.2 Other means of identification

Product number -
Other names 1-(tert-butoxycarbonyl)piperidine-4-sulfonic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:685514-01-6 SDS

685514-01-6Relevant articles and documents

Novel BCL-2/BCL-XL inhibitor, pharmaceutical composition and application

-

, (2020/11/12)

The invention relates to a compound for inhibiting the activity of Bcl-2/BCL-XL anti-apoptotic protein, a composition containing the compound and application of the compound serving as a synthetic drug, in particular to application of the compound serving as a drug for synthesizing a Bcl-2/BCL-XL anti-apoptotic protein inhibitor and application of the compound to cancer.

Preparation method of Venetoclax intermediate and product

-

Paragraph 0040; 0044-0046; 0050; 0054-0056, (2019/02/25)

The invention discloses a preparation method of a Venetoclax intermediate. 5-bromine-7-azaindole (II) is used as a raw material; an upper protecting group generates 5-bromine-1-(Triisopropyl silicyl)-1H-pyrrolo[2,3-b]pyridine (III); a compound (III) and T

Solid dispersions containing an apoptosis-inducing agent

-

Page/Page column 12, (2019/03/15)

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, AND/OR A BCL-2 INHIBITOR

-

Paragraph 00745, (2016/02/29)

Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms (PI3K-γ,δ, PI3K-γ, and PI3K-δ), a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a B-cell lymphoma-2 (BCL-2) inhibitor are described. In some embodiments, the invention provides therapeutic combinations of a PI3K-δ inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a BCL-2 and BTK inhibitor.

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

-

Paragraph 0227, (2014/09/30)

Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.

SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT

-

Page/Page column 11, (2012/06/15)

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}- sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

-

Page/Page column 80, (2011/12/14)

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

-

Page/Page column 56, (2010/08/07)

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

-

Page/Page column 119, (2010/12/29)

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Synthesis of functionalized 7-azaindoles via directed ortho-metalations

L'Heureux, Alexandre,Thibault, Carl,Ruel, Réjean

, p. 2317 - 2319 (2007/10/03)

Functionalization at C-5 of 4-fluoro- and 4-chloro-1-triisopropylsilyl-7- azaindole, 1 and 2, respectively, leads to a variety of new substituted 7-azaindole derivatives. We also describe two approaches to introduce functionality at C-6.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 685514-01-6